TRAIL/TNFSF10 Antibody (B-T24) [DyLight 755]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-14605IR
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA, Flow Cytometry
Label
DyLight 755 (Excitation = 754 nm, Emission = 776 nm)
Antibody Source
Monoclonal Mouse IgG1 kappa Clone # B-T24
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for TRAIL/TNFSF10 Antibody (B-T24) [DyLight 755]
Immunogen
Recombinant human TRAIL/TNFSF10
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1 kappa
Applications for TRAIL/TNFSF10 Antibody (B-T24) [DyLight 755]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: TRAIL/TNFSF10
Long Name
TNF-related Apoptosis-inducing Ligand
Alternate Names
CD253, TNFSF10
Gene Symbol
TNFSF10
Additional TRAIL/TNFSF10 Products
Product Documents for TRAIL/TNFSF10 Antibody (B-T24) [DyLight 755]
Product Specific Notices for TRAIL/TNFSF10 Antibody (B-T24) [DyLight 755]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...